Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri scMRD Assay for AML. Learn More
X
Scientific presentation

Investigation of AML clonal architecture with mutational and immunophenotypic profiling simultaneously from the same cell(s)


Linde Miles, PhD
Description

Acute myeloid leukemia (AML) is a molecularly diverse hematology disease with a poor survival rate. Only 25% of patients diagnosed survive. Therefore, it is important to gain a better understanding of the disease progression by using new technologies like single-cell DNA sequencing. Leukemogenesis is thought to be a stepwise process. However, bulk sequencing only infers the order of mutation acquisition. Linde Miles, of Ross Levine’s lab at Memorial Sloan Kettering Cancer Center, shares findings from her study where she immunophenotyped and genotyped AML samples to track the order of mutations using a custom molecular panel, covering key genes for AML, MPN, and MDS. Furthermore, through a simple add-on to the workflow, she confirmed protein expression with molecular data to understand enrichment and differentiation patterns. Discover how the Tapestri Platform provides a true multi-omics approach for deeper insight into systems biology and patterns of tumor evolution, therapy response, and resistance.



VIEW


Scientific presentation
AML Single-cell Multi-omics MRD (scMRD) and the Horizon of Clinical Utility
Aaron Llanso
AMP 2022 (2022)
Scientific presentation
Molecular Analysis of Acute Myeloid Leukemia in Morphologic Remission
Sanam Loghavi, MD
AMP 2022 (2022)
Scientific presentation
Considerations, Strategies, and Advances in Early Drug Development to Mitigate Clinical Holds and Achieve Successful CGT Outcomes
Azadeh Golipour, PhD, AVROBIO
J. Kelly Ganjei, AmplifyBio
Scott R. Burger, MD, Advanced Cell and Gene Therapy
Matthew Cato
(2022)
Scientific presentation
Overview on Mission Bio’s Applications
Simone Formisano
Mission Bio EU Heme Symposium (2022)
REQUEST QUOTE